Neuroleptic malignant syndrome during low dosed neuroleptic medication in first-episode psychosis: a case report |
| |
| Authors: | Friedrich Gönner Ralf Baumgartner Daniel Schüpbach M. C. G. Merlo |
| |
| Affiliation: | (1) Department of Neurology, University Hospital of Berne, Inselspital, Freiburgstrasse, CH-3010 Bern, Switzerland, CH;(2) Psychiatric Institutions, University of Berne, CH-3000 Bern 60, Switzerland e-mail: merlo@puk.unibe.ch Fax: +41-31-9309404, CH |
| |
| Abstract: | Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal side-effect of antipsychotic drug therapy, especially of dopamine receptor antagonists. As a dose relationship has been postulated, low dose neuroleptization would be expected to help to avoid this side-effect. In contrast, we report on a 21-year-old female following low dose fluphenazine treatment with 2.5 mg/day. The patient recovered from NMS after 3 days of dantrolene administration. Eventually, remission from psychotic symptoms was achieved with clozapine. At 8-month follow-up, psychopathology remained stable and there were no more signs of NMS. Received: 8 July 1998 / Final version: 6 November 1998 |
| |
| Keywords: | Neuroleptic malignant syndrome First-episode psychosis Low-dose medication Fluphenazine Clozapine |
| 本文献已被 SpringerLink 等数据库收录！ |
|
